Search research articles
Contact Us
Filters
Showing results (131-140 of 168) with videos related to
Page
of 17
Sort By:
Minerva Urology and Nephrology
|
January 13, 2021
A systematic review of nerve-sparing surgery for high-risk prostate cancer
Andrey Morozov, Eric Barret, Domenico Veneziano, et al.
Therapeutic Advances in Medical Oncology
|
June 3, 2024
PARP inhibitors in prostate cancers, is it time for combinations?
Diego Teyssonneau, Charles Dariane, Eric Barret, et al.
Cancers
|
September 10, 2021
Intraoperative Digital Analysis of Ablation Margins (DAAM) by Fluorescent Confocal Microscopy to Improve Partial Prostate Gland Cryoablation Outcomes
Oscar Selvaggio, Ugo Giovanni Falagario, Salvatore Mariano Bruno, et al.
The Journal of Urology
|
November 28, 2022
A Multicenter, Randomized, Single-blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-intermediate Risk Prostate Cancer
Jean de la Rosette, Jose Dominguez-Escrig, Kai Zhang, et al.
The French Journal of Urology
|
November 24, 2024
French AFU Cancer Committee Guidelines - Update 2024-2026: Prostate cancer - Diagnosis and management of localised disease
Guillaume Ploussard, Michaël Baboudjian, Eric Barret, et al.
BJU International
|
August 13, 2018
Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer
Charlotte Fenioux, Christophe Louvet, Emilie Charton, et al.
European Urology
|
February 7, 2022
Restaging of Patients with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy Using [<sup>68</sup>Ga]-PSMA-11 Positron Emission Tomography/Computed Tomography: Impact on Disease Management
Mathieu Gauthé, Paul Sargos, Nicolas Benziane Ouaritini, et al.
The French Journal of Urology
|
November 24, 2024
French AFU Cancer Committee Guidelines - Update 2024-2026: Prostate cancer - Management of metastatic disease and castration resistance
Guillaume Ploussard, Charles Dariane, Romain Mathieu, et al.
World Journal of Urology
|
July 23, 2015
A nomogram predicting the cancer-specific mortality in patients eligible for radical cystectomy evaluating clinical data and neoadjuvant cisplatinum-based chemotherapy
Ettore Di Trapani, Rafael Sanchez-Salas, Giorgio Gandaglia, et al.
JAMA Surgery
|
February 1, 2023
Effect of Focal vs Extended Irreversible Electroporation for the Ablation of Localized Low- or Intermediate-Risk Prostate Cancer on Early Oncological Control: A Randomized Clinical Trial
Kai Zhang, Jeremy Teoh, Pilar Laguna, et al.
Page
of 17
Search research articles
Search
Showing results (131-140 of 168) with videos related to
Sort By:
Page
of 17
Minerva Urology and Nephrology
|
January 13, 2021
A systematic review of nerve-sparing surgery for high-risk prostate cancer
Andrey Morozov, Eric Barret, Domenico Veneziano, et al.
Therapeutic Advances in Medical Oncology
|
June 3, 2024
PARP inhibitors in prostate cancers, is it time for combinations?
Diego Teyssonneau, Charles Dariane, Eric Barret, et al.
Cancers
|
September 10, 2021
Intraoperative Digital Analysis of Ablation Margins (DAAM) by Fluorescent Confocal Microscopy to Improve Partial Prostate Gland Cryoablation Outcomes
Oscar Selvaggio, Ugo Giovanni Falagario, Salvatore Mariano Bruno, et al.
The Journal of Urology
|
November 28, 2022
A Multicenter, Randomized, Single-blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-intermediate Risk Prostate Cancer
Jean de la Rosette, Jose Dominguez-Escrig, Kai Zhang, et al.
The French Journal of Urology
|
November 24, 2024
French AFU Cancer Committee Guidelines - Update 2024-2026: Prostate cancer - Diagnosis and management of localised disease
Guillaume Ploussard, Michaël Baboudjian, Eric Barret, et al.
BJU International
|
August 13, 2018
Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer
Charlotte Fenioux, Christophe Louvet, Emilie Charton, et al.
European Urology
|
February 7, 2022
Restaging of Patients with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy Using [<sup>68</sup>Ga]-PSMA-11 Positron Emission Tomography/Computed Tomography: Impact on Disease Management
Mathieu Gauthé, Paul Sargos, Nicolas Benziane Ouaritini, et al.
The French Journal of Urology
|
November 24, 2024
French AFU Cancer Committee Guidelines - Update 2024-2026: Prostate cancer - Management of metastatic disease and castration resistance
Guillaume Ploussard, Charles Dariane, Romain Mathieu, et al.
World Journal of Urology
|
July 23, 2015
A nomogram predicting the cancer-specific mortality in patients eligible for radical cystectomy evaluating clinical data and neoadjuvant cisplatinum-based chemotherapy
Ettore Di Trapani, Rafael Sanchez-Salas, Giorgio Gandaglia, et al.
JAMA Surgery
|
February 1, 2023
Effect of Focal vs Extended Irreversible Electroporation for the Ablation of Localized Low- or Intermediate-Risk Prostate Cancer on Early Oncological Control: A Randomized Clinical Trial
Kai Zhang, Jeremy Teoh, Pilar Laguna, et al.
Page
of 17